Symbols / INAB
INAB Chart
About
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 15.14M |
| Enterprise Value | -548.69K | Income | -20.66M | Sales | — |
| Book/sh | 2.87 | Cash/sh | 2.31 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -0.90 | PEG | — |
| P/S | — | P/B | 0.54 | P/C | — |
| EV/EBITDA | 0.03 | EV/Sales | — | Quick Ratio | 6.28 |
| Current Ratio | 6.91 | Debt/Eq | 22.42 | LT Debt/Eq | — |
| EPS (ttm) | -5.26 | EPS next Y | -1.72 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 16:00 | ROA | -80.39% |
| ROE | -189.72% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 9.77M |
| Shs Float | 3.30M | Short Float | 1.43% | Short Ratio | 1.13 |
| Short Interest | — | 52W High | 8.70 | 52W Low | 1.17 |
| Beta | -0.01 | Avg Volume | 285.00K | Volume | 20.27K |
| Target Price | $6.25 | Recom | Strong_buy | Prev Close | $1.51 |
| Price | $1.55 | Change | 2.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.25
Mean price target
2. Current target
$1.55
Latest analyst target
3. DCF / Fair value
$-13.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.55
Low
$4.00
High
$10.00
Mean
$6.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-14 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-02-12 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-02-11 | up | Jones Trading | Hold → Buy | $1 |
| 2024-11-26 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-13 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-08-12 | down | Jones Trading | Buy → Hold | — |
| 2024-06-14 | main | Jones Trading | Buy → Buy | $7 |
| 2024-06-14 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-05-13 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-04-10 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-03-18 | init | Laidlaw & Co. | — → Buy | $8 |
| 2024-03-15 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-03-13 | init | JonesTrading | — → Buy | $5 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-06-05 | reit | EF Hutton | Buy → Buy | $8 |
| 2023-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-04-26 | reit | HC Wainwright & Co. | — → Buy | $14 |
| 2023-04-24 | reit | Mizuho | — → Buy | $12 |
- Cancer T-cell biotech IN8bio to outline new milestones at TD Cowen - Stock Titan ue, 24 Feb 2026 13
- IN8bio Secures Up to $40.2 Million in Private Placement to Advance INB-619 and Extend Cash Runway Through 2027 - Quiver Quantitative Fri, 19 Dec 2025 08
- IN8bio Inc. Stock Surge: Decoding the Unexpected​ - StocksToTrade Fri, 19 Dec 2025 08
- T cell cancer therapy developer raises $20.1M to push new research - Stock Titan Fri, 19 Dec 2025 08
- IN8bio Announces Private Placement Financing - Nasdaq Fri, 19 Dec 2025 08
- What is the long term forecast for INAB stock - Day Trade & Free Accurate Trade Setup Notifications - mfd.ru Sun, 15 Feb 2026 04
- IN8bio (INAB) Is Going Wild: Tiny Cancer Stock, Massive Hype – But Should You Touch It? - AD HOC NEWS Fri, 13 Feb 2026 06
- IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Yahoo Finance hu, 06 Nov 2025 08
- IN8bio (NASDAQ: INAB) adds Ohio State to INB-100 Phase 1 in leukemia transplant setting - Stock Titan Wed, 29 Oct 2025 07
- INAB Stock Price and Chart — NASDAQ:INAB - TradingView Fri, 17 Dec 2021 08
- IN8bio’s Stock Tests Investors’ Nerves As Volatility Collides With Sparse Catalysts - AD HOC NEWS Fri, 13 Feb 2026 08
- IN8bio (INAB) - Zacks Investment Research Sat, 14 Nov 2020 18
- IN8bio gains extension to meet Nasdaq listing requirements - Investing.com Fri, 07 Feb 2025 08
- Guatemala Reports 38% Forest Coverage Nationwide - Latina Republic Mon, 22 Dec 2025 08
- IN8bio Elevates COO Kate Rochlin to President - TipRanks Mon, 09 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 724637 | 999999 | — | Stock Award(Grant) at price 1.38 per share. | FAIRBAIRN EMILY WANG | Director | — | 2025-12-22 00:00:00 | I |
| 1 | 72464 | 100000 | — | Stock Award(Grant) at price 1.38 per share. | BRANDT PETER C | Director | — | 2025-12-22 00:00:00 | D |
| 2 | 36232 | 50000 | — | Stock Award(Grant) at price 1.38 per share. | ROEMER ALAN S. | Director | — | 2025-12-22 00:00:00 | D |
| 3 | 36232 | 50000 | — | Stock Award(Grant) at price 1.38 per share. | HO WILLIAM TAI WEI | Chief Executive Officer | — | 2025-12-22 00:00:00 | D |
| 4 | 7247 | 10001 | — | Stock Award(Grant) at price 1.38 per share. | MCCALL PATRICK CPA | Chief Financial Officer | — | 2025-12-22 00:00:00 | D |
| 5 | 7247 | 10001 | — | Stock Award(Grant) at price 1.38 per share. | ROCHLIN KATE PH.D. | Chief Operating Officer | — | 2025-12-22 00:00:00 | D |
| 6 | 163934 | 30229 | — | Conversion of Exercise of derivative security at price 0.18 per share. | BRANDT PETER C | Director | — | 2025-04-30 00:00:00 | D |
| 7 | 113459 | 20922 | — | Conversion of Exercise of derivative security at price 0.18 per share. | ROEMER ALAN S. | Director | — | 2025-04-30 00:00:00 | D |
| 8 | 15000 | 2766 | — | Conversion of Exercise of derivative security at price 0.18 per share. | MCCALL PATRICK CPA | Chief Financial Officer | — | 2025-04-30 00:00:00 | D |
| 9 | 12295 | 2267 | — | Conversion of Exercise of derivative security at price 0.18 per share. | ROCHLIN KATE PH.D. | Chief Operating Officer | — | 2025-04-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -25.88M | -27.51M | -27.42M | -13.87M |
| TotalUnusualItems | -1.07M | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | -1.07M | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -30.44M | -30.01M | -28.52M | -14.65M |
| ReconciledDepreciation | 2.65M | 2.50M | 1.10M | 788.00K |
| EBITDA | -26.94M | -27.51M | -27.42M | -13.87M |
| EBIT | -29.60M | -30.01M | -28.52M | -14.65M |
| NetInterestIncome | 230.00K | 0.00 | ||
| InterestIncome | 230.00K | 0.00 | ||
| NormalizedIncome | -29.37M | -30.01M | -28.52M | -14.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -30.44M | -30.01M | -28.52M | -14.65M |
| TotalExpenses | 29.60M | 30.01M | 28.52M | 14.65M |
| TotalOperatingIncomeAsReported | -30.44M | -30.01M | -28.52M | -14.65M |
| DilutedAverageShares | 1.78M | 995.50K | 698.93K | 332.32K |
| BasicAverageShares | 1.78M | 995.50K | 698.93K | 332.32K |
| DilutedEPS | -17.10 | -30.00 | -40.80 | -44.10 |
| BasicEPS | -17.10 | -30.00 | -40.80 | -44.10 |
| DilutedNIAvailtoComStockholders | -30.44M | -30.01M | -28.52M | -14.65M |
| NetIncomeCommonStockholders | -30.44M | -30.01M | -28.52M | -14.65M |
| NetIncome | -30.44M | -30.01M | -28.52M | -14.65M |
| NetIncomeIncludingNoncontrollingInterests | -30.44M | -30.01M | -28.52M | -14.65M |
| NetIncomeContinuousOperations | -30.44M | -30.01M | -28.52M | -14.65M |
| PretaxIncome | -30.44M | -30.01M | -28.52M | -14.65M |
| OtherIncomeExpense | -1.07M | 330.00K | ||
| OtherNonOperatingIncomeExpenses | 330.00K | |||
| SpecialIncomeCharges | -1.07M | 0.00 | ||
| RestructuringAndMergernAcquisition | 1.07M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 230.00K | 0.00 | ||
| InterestIncomeNonOperating | 230.00K | 0.00 | ||
| OperatingIncome | -29.60M | -30.01M | -28.52M | -14.65M |
| OperatingExpense | 29.60M | 30.01M | 28.52M | 14.65M |
| OtherOperatingExpenses | -330.00K | |||
| ResearchAndDevelopment | 16.96M | 16.83M | 14.06M | 7.35M |
| SellingGeneralAndAdministration | 12.64M | 13.51M | 14.46M | 7.31M |
| GeneralAndAdministrativeExpense | 12.64M | 13.51M | 14.46M | 7.31M |
| OtherGandA | 12.64M | 13.51M | 14.46M | 7.31M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 2.42M | 1.44M | 818.17K | 626.04K |
| ShareIssued | 2.42M | 1.44M | 818.17K | 626.04K |
| TotalDebt | 5.03M | 4.89M | 5.87M | 2.41M |
| TangibleBookValue | 14.48M | 24.94M | 22.73M | 38.18M |
| InvestedCapital | 14.48M | 24.94M | 22.73M | 38.18M |
| WorkingCapital | 9.49M | 19.23M | 16.41M | 36.72M |
| NetTangibleAssets | 14.48M | 24.94M | 22.73M | 38.18M |
| CapitalLeaseObligations | 5.03M | 4.89M | 5.87M | 2.41M |
| CommonStockEquity | 14.48M | 24.94M | 22.73M | 38.18M |
| TotalCapitalization | 14.48M | 24.94M | 22.73M | 38.18M |
| TotalEquityGrossMinorityInterest | 14.48M | 24.94M | 22.73M | 38.18M |
| StockholdersEquity | 14.48M | 24.94M | 22.73M | 38.18M |
| RetainedEarnings | -121.66M | -91.22M | -61.21M | -32.69M |
| AdditionalPaidInCapital | 136.13M | 116.15M | 83.94M | 70.87M |
| CapitalStock | 7.00K | 4.00K | 3.00K | 2.00K |
| CommonStock | 7.00K | 4.00K | 3.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 6.47M | 8.77M | 10.31M | 4.04M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.38M | 3.38M | 4.49M | 1.78M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 3.38M | 3.38M | 4.49M | 1.78M |
| LongTermCapitalLeaseObligation | 3.38M | 3.38M | 4.49M | 1.78M |
| CurrentLiabilities | 3.08M | 5.39M | 5.82M | 2.26M |
| CurrentDebtAndCapitalLeaseObligation | 1.65M | 1.51M | 1.39M | 626.00K |
| CurrentCapitalLeaseObligation | 1.65M | 1.51M | 1.39M | 626.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 207.00K | 1.67M | 1.46M | 926.00K |
| PayablesAndAccruedExpenses | 1.23M | 2.21M | 2.97M | 704.00K |
| CurrentAccruedExpenses | 840.00K | 1.28M | 882.00K | 309.00K |
| Payables | 389.00K | 924.00K | 2.09M | 395.00K |
| AccountsPayable | 389.00K | 924.00K | 2.09M | 395.00K |
| TotalAssets | 20.94M | 33.71M | 33.04M | 42.22M |
| TotalNonCurrentAssets | 8.37M | 9.08M | 10.80M | 3.24M |
| OtherNonCurrentAssets | 541.00K | 511.00K | 507.00K | 409.00K |
| NonCurrentDeferredAssets | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 126.00K | 0.00 | ||
| OtherIntangibleAssets | 126.00K | |||
| NetPPE | 7.83M | 8.57M | 10.30M | 2.83M |
| AccumulatedDepreciation | -2.26M | -1.28M | -321.00K | -346.00K |
| GrossPPE | 10.09M | 9.86M | 10.62M | 3.18M |
| Leases | 3.92M | 3.92M | 3.90M | 0.00 |
| ConstructionInProgress | 0.00 | 182.00K | 29.00K | 403.00K |
| OtherProperties | 4.97M | 4.88M | 5.87M | 2.33M |
| MachineryFurnitureEquipment | 1.20M | 875.00K | 819.00K | 443.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 12.58M | 24.62M | 22.23M | 38.98M |
| OtherCurrentAssets | 298.00K | 270.00K | 232.00K | 52.00K |
| PrepaidAssets | 1.16M | 3.07M | 3.82M | 1.91M |
| CashCashEquivalentsAndShortTermInvestments | 11.12M | 21.28M | 18.18M | 37.02M |
| CashAndCashEquivalents | 11.12M | 21.28M | 18.18M | 37.02M |
| CashFinancial | 11.12M | 21.28M | 18.18M | 37.02M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.34M | -23.94M | -27.83M | -13.82M |
| RepaymentOfDebt | -794.00K | -798.00K | -615.00K | -709.00K |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 9.94M | 24.56M | 9.54M | 36.33M |
| CapitalExpenditure | -187.00K | -600.00K | -3.71M | -309.00K |
| EndCashPosition | 11.12M | 21.28M | 18.18M | 37.27M |
| OtherCashAdjustmentOutsideChangeinCash | -266.00K | -256.00K | ||
| BeginningCashPosition | 21.54M | 18.43M | 37.27M | 18.14M |
| ChangesInCash | -10.15M | 3.10M | -19.09M | 19.14M |
| FinancingCashFlow | 14.18M | 27.04M | 8.99M | 32.95M |
| CashFlowFromContinuingFinancingActivities | 14.18M | 27.04M | 8.99M | 32.95M |
| NetOtherFinancingCharges | -89.00K | -2.69M | ||
| ProceedsFromStockOptionExercised | 5.12M | 3.28M | 61.00K | 30.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 9.94M | 24.56M | 9.54M | 36.33M |
| CommonStockIssuance | 9.94M | 24.56M | 9.54M | 36.33M |
| NetIssuancePaymentsOfDebt | -794.00K | -798.00K | -615.00K | -709.00K |
| NetShortTermDebtIssuance | -174.00K | |||
| ShortTermDebtPayments | -174.00K | |||
| NetLongTermDebtIssuance | -794.00K | -798.00K | -615.00K | -709.00K |
| LongTermDebtPayments | -794.00K | -798.00K | -615.00K | -709.00K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -187.00K | -600.00K | -3.71M | -309.00K |
| CashFlowFromContinuingInvestingActivities | -187.00K | -600.00K | -3.71M | -309.00K |
| NetPPEPurchaseAndSale | -187.00K | -600.00K | -3.71M | -309.00K |
| PurchaseOfPPE | -187.00K | -600.00K | -3.71M | -309.00K |
| OperatingCashFlow | -24.15M | -23.34M | -24.12M | -13.51M |
| CashFlowFromContinuingOperatingActivities | -24.15M | -23.34M | -24.12M | -13.51M |
| ChangeInWorkingCapital | -1.41M | -204.00K | -170.00K | -1.84M |
| ChangeInOtherCurrentLiabilities | -838.00K | -708.00K | -414.00K | -39.00K |
| ChangeInOtherCurrentAssets | -20.00K | 0.00 | -97.00K | -159.00K |
| ChangeInPayablesAndAccruedExpense | -2.44M | -185.00K | 2.43M | 235.00K |
| ChangeInAccruedExpense | -1.91M | 796.00K | 924.00K | 554.00K |
| ChangeInPayable | -535.00K | -981.00K | 1.51M | -319.00K |
| ChangeInAccountPayable | -535.00K | -981.00K | 1.51M | -319.00K |
| ChangeInPrepaidAssets | 1.89M | 689.00K | -2.09M | -1.88M |
| StockBasedCompensation | 5.00M | 4.37M | 3.47M | 2.19M |
| DepreciationAmortizationDepletion | 2.65M | 2.50M | 1.10M | 788.00K |
| DepreciationAndAmortization | 2.65M | 2.50M | 1.10M | 788.00K |
| Depreciation | 2.65M | 2.50M | 1.10M | 788.00K |
| OperatingGainsLosses | 45.00K | |||
| GainLossOnSaleOfPPE | 45.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -30.44M | -30.01M | -28.52M | -14.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for INAB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|